Percentage specific lysis (51Cr release) of human tumor cell targets by apoptosis-resistant γδ-T cells and control αβ-T cells derived from healthy donors
| Tumor target* . | Lymphocyte source, age (y)/gender† . | Effector lymphocytes added and resultant specific lysis‡ . | |
|---|---|---|---|
| γδ-T cells . | αβ-T cells . | ||
| SK-MEL-3 | 38/M | 19.8 ± 0.9 | 3.5 ± 0.8 |
| 20/F | 16.2 ± 2.9 | 4.8 ± 1.9 | |
| 28/F | 16.6 ± 1.9 | 4.1 ± 2.0 | |
| SK-MEL-5 | 38/M | 14.1 ± 0.6 | 2.9 ± 0.9 |
| 28/F | 26.2 ± 5.4 | 5.3 ± 2.2 | |
| SK-MEL-28 | 38/M | 2.8 ± 0.7 | 0.5 ± 1.3 |
| 20/F | 1.4 ± 1.2 | 2.1 ± 0.4 | |
| HeLa | 41/F | 75.3 ± 2.0 | 9.1 ± 0.4 |
| 47/F | 65.7 ± 1.0 | 8.5 ± 1.2 | |
| OCI-Ly8 | 35/M | 60.1 ± 2.0 | 45.2 ± 4.7 |
| HSB-2 | 30/M | 23.0 ± 0.4 | ND |
| K562 | 47/F | 3.5 ± 0.2 | 1.6 ± 0.2 |
| Tumor target* . | Lymphocyte source, age (y)/gender† . | Effector lymphocytes added and resultant specific lysis‡ . | |
|---|---|---|---|
| γδ-T cells . | αβ-T cells . | ||
| SK-MEL-3 | 38/M | 19.8 ± 0.9 | 3.5 ± 0.8 |
| 20/F | 16.2 ± 2.9 | 4.8 ± 1.9 | |
| 28/F | 16.6 ± 1.9 | 4.1 ± 2.0 | |
| SK-MEL-5 | 38/M | 14.1 ± 0.6 | 2.9 ± 0.9 |
| 28/F | 26.2 ± 5.4 | 5.3 ± 2.2 | |
| SK-MEL-28 | 38/M | 2.8 ± 0.7 | 0.5 ± 1.3 |
| 20/F | 1.4 ± 1.2 | 2.1 ± 0.4 | |
| HeLa | 41/F | 75.3 ± 2.0 | 9.1 ± 0.4 |
| 47/F | 65.7 ± 1.0 | 8.5 ± 1.2 | |
| OCI-Ly8 | 35/M | 60.1 ± 2.0 | 45.2 ± 4.7 |
| HSB-2 | 30/M | 23.0 ± 0.4 | ND |
| K562 | 47/F | 3.5 ± 0.2 | 1.6 ± 0.2 |
Comparison of cytotoxicity at E:T ratios of 20:1.
Human tumor cell lines are described in “Materials and methods.”
Highly pure (>97%, not shown) apoptosis-resistant γδ- and control αβ-T lymphocytes were isolated by FACS from 21-day cultures of PBMC derived from healthy donors, as described in “Materials and methods.” Age and sex of PBMC donors are indicated.
Tumor target cells were labeled with 51Cr and cocultured with effector lymphocytes, as described in “Materials and methods.” Either apoptosis-resistant γδ-T cells or control αβ-T cells derived from the indicated donors were added at various E:T ratios (0.5:1 to 40:1). Percentage specific tumor lysis (mean ± SD of triplicate determinations) at an E:T ratio of 20:1 shown for comparison.
ND, not done.